
Global Generic Drugs Market Report and Forecast 2024-2032
Description
Global Generic Drugs Market Report and Forecast 2024-2032
Global Generic Drugs Market Report and Forecast 2024-2032
The global generic drugs market size was valued at USD 370.3 billion in 2023. It is expected to grow at a CAGR of 6.90% during the forecast period of 2024-2032, driven by the rising incidence of chronic diseases such as diabetes and hypertension. The market is experiencing robust growth and is expected to reach USD 678.2 billion by 2032.
Global Generic Drugs Market Analysis
The global generic drugs market is a critical segment of the pharmaceutical industry, providing cost-effective alternatives to branded drugs. Generics play a vital role in healthcare by increasing accessibility to essential medicines, reducing healthcare costs, and enhancing treatment options.
Market Drivers
- Patent Expirations of Blockbuster Drugs: A significant driver of the generic drugs market is the expiration of patents on blockbuster drugs. As patents expire, generic manufacturers can produce and market cheaper versions, increasing competition and making medications more affordable for patients.
- Rising Healthcare Costs: The growing burden of healthcare costs worldwide is propelling the demand for generic drugs. Governments and healthcare providers are increasingly adopting generics to manage budgets and provide affordable treatment options to a larger population.
- Increasing Prevalence of Chronic Diseases: The rising incidence of chronic diseases such as diabetes, hypertension, and cardiovascular disorders is driving the demand for long-term medication. Generics offer a cost-effective solution for chronic disease management, contributing to market growth.
- Government Initiatives and Support: Governments across the globe are promoting the use of generic drugs through favorable policies, subsidies, and regulatory support. These initiatives aim to reduce healthcare expenditure and ensure the availability of essential drugs.
- Growing Aging Population: The global aging population is increasing the demand for various medications. Older adults often require multiple drugs for managing chronic conditions, and generics provide a more affordable option, thereby driving market growth.
- Stringent Regulatory Requirements: The generic drugs market faces stringent regulatory requirements and approval processes. Manufacturers must demonstrate bioequivalence to branded drugs, which can be time-consuming and costly.
- Intense Competition: The market is highly competitive, with numerous players vying for market share. This intense competition can lead to price erosion, impacting profit margins for generic drug manufacturers.
- Supply Chain Disruptions: Supply chain disruptions, such as those caused by the COVID-19 pandemic, can affect the production and distribution of generic drugs. Ensuring a stable supply chain is a significant challenge for the industry.
- Intellectual Property Issues: Navigating intellectual property rights and patent litigations can be challenging for generic manufacturers. Branded drug companies often employ strategies to extend their patents, delaying the entry of generics into the market.
- Expansion in Emerging Markets: Emerging markets present significant growth opportunities for generic drugs due to their large populations and increasing healthcare needs. Improving healthcare infrastructure and rising awareness about generics can drive market expansion in these regions.
- Biosimilars: The development and approval of biosimilars (generic versions of biologic drugs) offer a lucrative opportunity for market growth. Biosimilars can provide cost-effective treatment options for complex diseases like cancer and autoimmune disorders.
- Technological Advancements: Advancements in manufacturing technologies and pharmaceutical R&D can enhance the efficiency and quality of generic drug production. Implementing innovative technologies can reduce costs and improve product offerings.
- Collaborations and Strategic Alliances: Collaborations and strategic alliances between generic drug manufacturers and healthcare providers can facilitate market penetration and expand the reach of generic drugs. These partnerships can also enhance R&D capabilities and streamline the approval process.
- Focus on Specialty Generics: Specialty generics, which include complex generics and injectables, represent a growing segment with high potential. Developing and marketing specialty generics can offer higher profit margins and address unmet medical needs.
Here are some key trends in the global generic drugs market:
- Rising Adoption of Biosimilars
- Increasing Focus on Specialty Generics
- Expansion in Emerging Markets
- Stringent Regulatory Approvals
- Consolidation and Mergers & Acquisitions
- Technological Advancements in Manufacturing
- Growing Emphasis on Cost Containment
Global Generic Drugs Market Segmentation
Market Breakup by Therapy Area
- Cardiovascular
- Dermatology
- Respiratory
- Oncology
- Rheumatology
- Others
Market Breakup by Route of Administration
- Oral
- Injectables
- Dermal/Topical
- Inhalers
- Others
Market Breakup by Distribution Channels
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Generic Drugs Market Competitive Landscape
The competitive landscape of the global generic drugs market is dynamic, with key players including Teva Pharmaceutical Industries Ltd, Viatris Inc., Sun Pharmaceutical Industries Ltd, Lupin, AstraZeneca, Almirall, S.A, Takeda Pharmaceutical Company Limited, GSK plc, Bausch + Lomb, Novartis AG, Sanofi, Pfizer Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals PLC, and Aurobindo Pharma. Common market activities include mergers and acquisitions to enhance market share and capabilities, significant research initiatives aimed at developing cost-effective generics, frequent product introductions to expand portfolios, and strategic partnerships to foster innovation and streamline manufacturing and distribution processes. These activities collectively drive competition and growth in the generic drugs market.
Key Questions Answered in the Report
- What is the current and future performance of the generic drugs market?
- What are the main challenges facing the generic drugs market?
- What are the key drivers of the generic drugs market?
- What emerging trends are shaping the future of the generic drugs market?
- How does the expiration of patents on blockbuster drugs drive the generic drugs market?
- How does the rising incidence of chronic diseases impact the demand for generic medications?
- How are global government initiatives promoting the use of generic drugss and reducing healthcare costs?
- How do biosimilars offer a lucrative opportunity for market growth in treating complex diseases?
- What are the common strategies used by key players in the generic drugs market?
- The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the global generic drugs market from 2017-2032.
- The research report provides the latest information on the market drivers, challenges, and opportunities in the generic drugs market.
- The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
- Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the global generic drugs industry and its attractiveness.
- The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
Table of Contents
200 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Generic Drugs Market Overview
- 3.1 Global Generic Drugs Market Historical Value (2017-2023)
- 3.2 Global Generic Drugs Market Forecast Value (2024-2032)
- 4 Global Generic Drugs Market Landscape*
- 4.1 Global Generic Drugs: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Generic Drugs: Product Landscape
- 4.2.1 Analysis by Therapy Area
- 4.2.2 Analysis by Route of Administration
- 4.2.3 Analysis by Distribution Channels
- 5 Global Generic Drugs Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Model
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Generic Drugs Market Segmentation (2017-2032)
- 6.1 Global Generic Drugs Market (2017-2032) by Therapy Area
- 6.1.1 Market Overview
- 6.1.2 Cardiovascular
- 6.1.3 Dermatology
- 6.1.4 Respiratory
- 6.1.5 Oncology
- 6.1.6 Rheumatology
- 6.1.7 Others
- 6.2 Global Generic Drugs Market (2017-2032) by Route of Administration
- 6.2.1 Market Overview
- 6.2.2 Oral
- 6.2.3 Injectables
- 6.2.4 Dermal/Topical
- 6.2.5 Inhalers
- 6.2.6 Others
- 6.3 Global Generic Drugs Market (2017-2032) by Distribution Channels
- 6.3.1 Market Overview
- 6.3.2 Hospital Pharmacy
- 6.3.3 Retail Pharmacy
- 6.3.4 Online Pharmacy
- 6.3.5 Others
- 6.4 Global Generic Drugs Market (2017-2032) by Region
- 6.4.1 Market Overview
- 6.4.2 North America
- 6.4.3 Europe
- 6.4.4 Asia Pacific
- 6.4.5 Latin America
- 6.4.6 Middle East and Africa
- 7 North America Generic Drugs Market (2017-2032)
- 7.1 North America Generic Drugs Market (2017-2032) by Therapy Area
- 7.1.1 Market Overview
- 7.1.2 Cardiovascular
- 7.1.3 Dermatology
- 7.1.4 Respiratory
- 7.1.5 Oncology
- 7.1.6 Rheumatology
- 7.1.7 Others
- 7.2 North America Generic Drugs Market (2017-2032) by Route of Administration
- 7.2.1 Market Overview
- 7.2.2 Oral
- 7.2.3 Injectables
- 7.2.4 Dermal/Topical
- 7.2.5 Inhalers
- 7.2.6 Others
- 7.3 North America Generic Drugs Market (2017-2032) by Country
- 7.3.1 United States of America
- 7.3.2 Canada
- 8 Europe Generic Drugs Market (2017-2032)
- 8.1 Europe Generic Drugs Market (2017-2032) by Therapy Area
- 8.1.1 Market Overview
- 8.1.2 Cardiovascular
- 8.1.3 Dermatology
- 8.1.4 Respiratory
- 8.1.5 Oncology
- 8.1.6 Rheumatology
- 8.1.7 Others
- 8.2 Europe Generic Drugs Market (2017-2032) by Route of Administration
- 8.2.1 Market Overview
- 8.2.2 Oral
- 8.2.3 Injectables
- 8.2.4 Dermal/Topical
- 8.2.5 Inhalers
- 8.2.6 Others
- 8.3 Europe Generic Drugs Market (2017-2032) by Country
- 8.3.1 United Kingdom
- 8.3.2 Germany
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Others
- 9 Asia Pacific Generic Drugs Market (2017-2032)
- 9.1 Asia Pacific Generic Drugs Market (2017-2032) by Therapy Area
- 9.1.1 Market Overview
- 9.1.2 Cardiovascular
- 9.1.3 Dermatology
- 9.1.4 Respiratory
- 9.1.5 Oncology
- 9.1.6 Rheumatology
- 9.1.7 Others
- 9.2 Asia Pacific Generic Drugs Market (2017-2032) by Route of Administration
- 9.2.1 Market Overview
- 9.2.2 Oral
- 9.2.3 Injectables
- 9.2.4 Dermal/Topical
- 9.2.5 Inhalers
- 9.2.6 Others
- 9.3 Asia Pacific Generic Drugs Market (2017-2032) by Country
- 9.3.1 China
- 9.3.2 Japan
- 9.3.3 India
- 9.3.4 ASEAN
- 9.3.5 Australia
- 9.3.6 Others
- 10 Latin America Generic Drugs Market (2017-2032)
- 10.1 Latin America Generic Drugs Market (2017-2032) by Therapy Area
- 10.1.1 Market Overview
- 10.1.2 Cardiovascular
- 10.1.3 Dermatology
- 10.1.4 Respiratory
- 10.1.5 Oncology
- 10.1.6 Rheumatology
- 10.1.7 Others
- 10.2 Latin America Generic Drugs Market (2017-2032) by Route of Administration
- 10.2.1 Market Overview
- 10.2.2 Oral
- 10.2.3 Injectables
- 10.2.4 Dermal/Topical
- 10.2.5 Inhalers
- 10.2.6 Others
- 10.3 Latin America Generic Drugs Market (2017-2032) by Country
- 10.3.1 Brazil
- 10.3.2 Argentina
- 10.3.3 Mexico
- 10.3.4 Others
- 11 Middle East and Africa Generic Drugs Market (2017-2032)
- 11.1 Middle East and Africa Generic Drugs Market (2017-2032) by Therapy Area
- 11.1.1 Market Overview
- 11.1.2 Cardiovascular
- 11.1.3 Dermatology
- 11.1.4 Respiratory
- 11.1.5 Oncology
- 11.1.6 Rheumatology
- 11.1.7 Others
- 11.2 Middle East and Africa Generic Drugs Market (2017-2032) by Route of Administration
- 11.2.1 Market Overview
- 11.2.2 Oral
- 11.2.3 Injectables
- 11.2.4 Dermal/Topical
- 11.2.5 Inhalers
- 11.2.6 Others
- 11.3 Middle East and Africa Generic Drugs Market (2017-2032) by Country
- 11.3.1 Saudi Arabia
- 11.3.2 United Arab Emirates
- 11.3.3 Nigeria
- 11.3.4 South Africa
- 11.3.5 Others
- 12 Regulatory Framework
- 12.1 Regulatory Overview
- 12.1.1 US FDA
- 12.1.2 EU EMA
- 12.1.3 INDIA CDSCO
- 12.1.4 JAPAN PMDA
- 12.1.5 Others
- 13 Patent Analysis
- 13.1 Analysis by Type of Patent
- 13.2 Analysis by Publication year
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 13.7 Analysis by Key Players
- 14 Grants Analysis
- 14.1 Analysis by Year
- 14.2 Analysis by Amount Awarded
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Grant Housing Material
- 14.5 Analysis by Funding Institute
- 14.6 Analysis by Departments
- 14.7 Analysis by Recipient Organization
- 15 Funding and Investment Analysis
- 15.1 Analysis by Funding Instances
- 15.2 Analysis by Type of Funding
- 15.3 Analysis by Funding Amount
- 15.4 Analysis by Leading Players
- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
- 16.1 Analysis by Partnership Instances
- 16.2 Analysis by Type of Partnership
- 16.3 Analysis by Leading Players
- 16.4 Analysis by Geography
- 17 Supplier Landscape
- 17.1 Market Share by Top 5 Companies
- 17.2 Teva Pharmaceutical Industries Ltd
- 17.2.1 Financial Analysis
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Mergers and Acquisitions
- 17.2.5 Certifications
- 17.3 Viatris Inc.
- 17.3.1 Financial Analysis
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Mergers and Acquisitions
- 17.3.5 Certifications
- 17.4 Sun Pharmaceutical Industries Ltd
- 17.4.1 Financial Analysis
- 17.4.2 Product Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Mergers and Acquisitions
- 17.4.5 Certifications
- 17.5 Lupin
- 17.5.1 Financial Analysis
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Mergers and Acquisitions
- 17.5.5 Certifications
- 17.6 AstraZeneca
- 17.6.1 Financial Analysis
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Mergers and Acquisitions
- 17.6.5 Certifications
- 17.7 Almirall, S.A
- 17.7.1 Financial Analysis
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Mergers and Acquisitions
- 17.7.5 Certifications
- 17.8 Takeda Pharmaceutical Company Limited
- 17.8.1 Financial Analysis
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Mergers and Acquisitions
- 17.8.5 Certifications
- 17.9 GSK plc
- 17.9.1 Financial Analysis
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Mergers and Acquisitions
- 17.9.5 Certifications
- 17.10 Bausch + Lomb
- 17.10.1 Financial Analysis
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Mergers and Acquisitions
- 17.10.5 Certifications
- 17.11 Novartis AG
- 17.11.1 Financial Analysis
- 17.11.2 Product Portfolio
- 17.11.3 Demographic Reach and Achievements
- 17.11.4 Mergers and Acquisitions
- 17.11.5 Certifications
- 17.12 Sanofi
- 17.12.1 Financial Analysis
- 17.12.2 Product Portfolio
- 17.12.3 Demographic Reach and Achievements
- 17.12.4 Mergers and Acquisitions
- 17.12.5 Certifications
- 17.13 Pfizer Inc.
- 17.13.1 Financial Analysis
- 17.13.2 Product Portfolio
- 17.13.3 Demographic Reach and Achievements
- 17.13.4 Mergers and Acquisitions
- 17.13.5 Certifications
- 17.14 Fresenius SE & Co. KGaA
- 17.14.1 Financial Analysis
- 17.14.2 Product Portfolio
- 17.14.3 Demographic Reach and Achievements
- 17.14.4 Mergers and Acquisitions
- 17.14.5 Certifications
- 17.15 Hikma Pharmaceuticals PLC
- 17.15.1 Financial Analysis
- 17.15.2 Product Portfolio
- 17.15.3 Demographic Reach and Achievements
- 17.15.4 Mergers and Acquisitions
- 17.15.5 Certifications
- 17.16 Aurobindo Pharma
- 17.16.1 Financial Analysis
- 17.16.2 Product Portfolio
- 17.16.3 Demographic Reach and Achievements
- 17.16.4 Mergers and Acquisitions
- 17.16.5 Certifications
- 18 Global Generic Drugs Market – Distribution Model (Additional Insight)
- 18.1 Overview
- 18.2 Potential Distributors
- 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
- 20.1 Very Small Companies
- 20.2 Small Companies
- 20.3 Mid-Sized Companies
- 20.4 Large Companies
- 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
- 21.1 Government Funded
- 21.2 Private Insurance
- 21.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.